Design Therapeutics (DSGN)
(Delayed Data from NSDQ)
$4.75 USD
+0.04 (0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $4.76 +0.01 (0.21%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Design Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 78 | 68 | 36 | 9 | 0 |
Income After Depreciation & Amortization | -78 | -68 | -36 | -8 | 0 |
Non-Operating Income | 11 | 4 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -67 | -63 | -36 | -8 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -67 | -63 | -36 | -8 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -67 | -63 | -36 | -8 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -84 | -69 | -36 | -8 | 0 |
Depreciation & Amortization (Cash Flow) | -6 | -1 | 0 | 0 | NA |
Income After Depreciation & Amortization | -78 | -68 | -36 | -8 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 55.99 | 55.71 | 45.94 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.19 | -1.14 | -0.77 | NA | NA |
Diluted Net EPS (GAAP) | -1.19 | -1.14 | -0.77 | NA | NA |
Fiscal Year end for Design Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 15.05 | 14.40 | 15.12 | 18.83 | 22.59 |
Income After SG&A, R&D, and Dept/Amort Expenses | -15.05 | -14.40 | -15.12 | -18.83 | -22.59 |
Non-Operating Income | 3.25 | 3.30 | 3.28 | 3.03 | 2.66 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -11.79 | -11.11 | -11.84 | -15.79 | -19.94 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -11.79 | -11.11 | -11.84 | -15.79 | -19.94 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -11.79 | -11.11 | -11.84 | -15.79 | -19.94 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 56.56 | 56.49 | 56.09 | 55.99 | 55.95 |
Diluted EPS Before Non-Recurring Items | -0.21 | -0.20 | -0.21 | -0.28 | -0.36 |
Diluted Net EPS (GAAP) | -0.21 | -0.20 | -0.20 | -0.28 | -0.36 |